HeartSciences Inc (HSCS) Actualités

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences...

HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form EFFECT - Notice of Effectiveness

HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

Southlake, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences...

HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.

Southlake, TX, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

Form 8-K - Current report

Form 8-K - Current report

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Southlake, TX, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:...

Form D - Notice of Exempt Offering of Securities

Form S-3 - Registration statement under Securities Act of 1933